Sakuranin Is a Novel Anti‐Inflammatory Agent Targeting TLR4–NF‐κB Signaling Pathways
Chemistry & Biodiversity · 2025
DOI: 10.1002/cbdv.202501167 ↗At a glance
Journal article in Chemistry & Biodiversity, 2025. Written by Jayasingha Arachchige Chathuranga Chanaka Jayasingha and 5 co-authors. Institution: Department of Marine Life Science, Jeju National University, Jeju, Republic of Korea. Major MEDLINE topics: Toll-Like Receptor 4, NF-kappa B, Signal Transduction, Anti-Inflammatory Agents. 41 references.
Abstract (original language)
Sakuranin (SKR) is naturally occurring compound known for its anti‐inflammatory and antioxidant activities; however, its precise molecular mechanisms in modulating inflammation through toll‐like receptor 4 (TLR4) signaling remain unclear. This study investigates the anti‐inflammatory effects of SKR in lipopolysaccharide (LPS)‐stimulated RAW 264.7 macrophages and zebrafish larvae, focusing on the TLR4–nuclear factor‐kappa B (NF‐κB) signaling pathway. SKR significantly inhibited the production of nitric oxide (NO), prostaglandin E 2 (PGE 2 ), interleukin‐12 (IL‐12), and tumor necrosis factor‐alpha (TNF‐α), while downregulating the expression of inducible NO synthase (NOS2) and cyclooxygenase‐2 (COX2) at both transcriptional and translational levels. In vivo, SKR reduced LPS‐induced mortality, restored cardiac function, and attenuated immune cell infiltration in zebrafish larvae, further underscoring its systemic anti‐inflammatory effects. Mechanistic studies revealed that SKR inhibited NF‐κB nuclear translocation and directly interacted with the TLR4/myeloid differentiation factor 2 (MD2) complex, thereby disrupting LPS–TLR4 signaling. Molecular docking and colocalization analyses confirmed that SKR directly binds TLR4, potentially interfering with LPS recognition and downstream pro‐inflammatory signaling activation. Collectively, these findings highlight SKR as a potent modulator of TLR4‐mediated inflammation, offering promising therapeutic potential for inflammatory disorders. Further investigations into its pharmacokinetics, bioavailability, and long‐term efficacy in chronic inflammatory conditions are warranted to support its clinical applications.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Marine Life Science, Jeju National University, Jeju, Republic of Korea.
- Forest Microbiology and Application Division, National Institute of Forest Science, Suwon, Republic of Korea.
- Key Laboratory of Advanced Technology for Drug Preparation, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, Henan, China.
- Department of Biochemistry, College of Korean Medicine, Dong-Eui University, Busan, Republic of Korea.
- Biological Resources Research Department, Nakdonggang National Institute of Biological Resources, Sangju, Republic of Korea.
ORCID profiles: Gi-Young Kim
Cite
APA
Jayasingha, J. A. C. C., Lee, K. T., Jin, C. Y., Choi, Y. H., Lee, C. S., & Kim, G. Y. (2025). Sakuranin Is a Novel Anti‐Inflammatory Agent Targeting TLR4–NF‐κB Signaling Pathways. Chemistry & Biodiversity. https://doi.org/10.1002/cbdv.202501167
Vancouver
Jayasingha JACC, Lee KT, Jin CY, Choi YH, Lee CS, Kim GY. Sakuranin Is a Novel Anti‐Inflammatory Agent Targeting TLR4–NF‐κB Signaling Pathways. Chemistry & Biodiversity. 2025. doi:10.1002/cbdv.202501167
BibTeX
@article{Jayasingha2025,
author = {Jayasingha, Jayasingha Arachchige Chathuranga Chanaka and Lee, Kyoung Tae and Jin, Cheng-Yun and Choi, Yung Hyun and Lee, Chang Soo and Kim, Gi-Young},
title = {Sakuranin Is a Novel Anti‐Inflammatory Agent Targeting TLR4–NF‐κB Signaling Pathways},
journal = {Chemistry & Biodiversity},
year = {2025},
doi = {10.1002/cbdv.202501167}
}
EUVIMED